Drug combination for the treatment of depression and related disorders comprising mirtazapine

Abstract

The invention relates to a combination comprising an amount of mirtazapine, or a pharmaceutically acceptable salt or solvate thereof, and an amount of gepirone, or a pharmaceutically acceptable salt or solvate thereof, optionally in association with one or more pharmaceutically acceptable carriers, whereby the amount of gepirone and the amount of mirtazapine are such that the effect of the composition is more favourable than the added effects of the amounts of each drug separately. This combination can be used in the treatment of depression and related disorders, whereby the invention also provides for a new method of treatment of depression and related disorders.

1 . A combination, comprising: 
 mirtazapine, or a pharmaceutically acceptable salt or solvate thereof, and    gepirone, or a pharmaceutically acceptable salt or solvate thereof,    optionally in association with one or more pharmaceutically acceptable carriers.    
     
     
         2 . The combination according to  claim 1 , wherein the combination comprises a pharmaceutical composition, comprising both mirtazapine and gepirone, optionally in association with one or more pharmaceutically acceptable carriers.  
     
     
         3 . (canceled).  
     
     
         4 . (canceled).  
     
     
         5 . (canceled).  
     
     
         6 . (canceled).  
     
     
         7 . A patient pack, comprising: 
 means for administering metered unit doses, said metered unit doses comprising:    mirtazapine and    gepirone.    
     
     
         8 . The patient pack according to  claim 7 , wherein the means provided is a blister pack.  
     
     
         9 . A patient pack, comprising: 
 metered unit doses of the combination according to  claim 2.